Consequently, the theoretical decoupling of cytotoxic effects and ACE2 upregulation through the administration of agents inhibiting ACE2 emerges as a promising therapeutic strategy in the nuanced management of aggressive breast cancer. This evidence concerns the gene ACE2 and breast carcinoma.